

Satsuma Pharmaceuticals, Inc.

## Satsuma Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference

**South San Francisco, CA, September 28, 2021** – [Satsuma Pharmaceuticals, Inc.](#) (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today announced that John Kollins, its President and Chief Executive Officer, is scheduled to present at the Cantor Virtual Global Healthcare Conference and invites investors to participate via webcast and in one-on-one meetings. Please see additional details below:

### Cantor Virtual Global Healthcare Conference

Date: Thursday, September 30<sup>th</sup>

Time: 2:40 to 3:10 p.m. ET

Presenter: John Kollins, President & CEO of Satsuma Pharmaceuticals

Webcast: [Registration Link](#) – [Click Here](#)

*\* a replay will be available following the presentation for **90** days*

Please contact your representative at Cantor Fitzgerald to schedule a virtual one-on-one meeting with Satsuma Pharmaceuticals during the respective conference.

For more information about the *Cantor Virtual Global Healthcare Conference*, please refer to the Cantor Fitzgerald [conference website](#).

### About Satsuma Pharmaceuticals and STS101

Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic product, STS101, for the acute treatment of migraine. STS101 is a unique and proprietary nasal powder formulation of the well-established anti-migraine drug, dihydroergotamine mesylate (DHE), administered via Satsuma's proprietary 2<sup>nd</sup>-generation nasal delivery device. STS101 is designed to provide significant benefits versus existing acute treatments for migraine, including the combination of quick and convenient self-administration and other clinical advantages, that current DHE liquid nasal spray products and injectable dosage forms lack. Satsuma's dry powder DHE formulation has demonstrated fast absorption, rapid achievement of high DHE plasma concentrations which Satsuma believes is necessary for early efficacy, and sustained plasma levels over time with low dose to dose variability. Although DHE has long been recommended in published migraine treatment guidelines as a first-line acute treatment option for migraine and has significant advantages versus other anti-migraine treatments for many patients, disadvantages of current DHE liquid nasal spray and injectable products, including invasive and burdensome administration processes and/or sub-optimal clinical performance, have limited the widespread use of DHE. Featuring a compact and convenient dosage form, STS101 is designed to overcome these shortcomings and provide patients an improved therapeutic solution for acutely treating migraines that consistently delivers robust clinical performance.

Satsuma is headquartered in South San Francisco, California with operations in both California and Research Triangle Park, North Carolina. For further information, please visit [www.satsumarx.com](http://www.satsumarx.com).

### **INVESTOR AND CORPORATE CONTACTS:**

Corey Davis, PhD  
LifeSci Advisors, LLC  
[cdavis@lifesciadvisors.com](mailto:cdavis@lifesciadvisors.com)

Tom O'Neil, Chief Financial Officer  
Satsuma Pharmaceuticals, Inc.  
[tom@satsumarx.com](mailto:tom@satsumarx.com)

---

<https://investors.satsumarx.com/2021-09-28-Satsuma-Pharmaceuticals-to-Present-at-the-Cantor-Virtual-Global-Healthcare-Conference>